Concentration of Credit

12 Months Ended

Dec. 31, 2016

Risks and Uncertainties [Abstract]

Concentration of Credit

Concentration of Credit

On June 30, 2016, the Company terminated its agreement with the distributor for a significant portion of its Carticel sales. Prior to June 30, 2016, the Company sold Carticel to a distributor, which subsequently resold Carticel to patients and healthcare providers. The Company has transitioned to a new provider, Dohmen Life Science Services, LLC (DLSS) who provides a patient support services program but does not act as a distributor. The Company's receivables risk is now spread among various hospitals, individual patients, and third-party payers and therefore, the concentration of credit risk shifted for the Company.

Revenue from one customer, a distributor in the U.S., represented 31% and 66% of total revenue during the years ended December 31,2016 and 2015, respectively. Accounts receivable from the same customer accounted for 1% and 76% of the outstanding accounts receivable as of  December 31,2016 and 2015, respectively. The next largest customer represented 11% and 12% of revenue for the year ended December 31,2016 and 2015, respectively. Accounts receivable from the next largest customer accounted for 5% and 8% of the outstanding accounts receivable as of December 31,2016 and 2015, respectively.